×

Statement from EMA about Advagraf® and cardiovascular medicine

24 October 2011

The European Medicines Agency, EMA, has decided to immediately recall some batches of Advagraf® (tacrolimus) 0.5 mg prolonged-release hard capsules from pharmacies and wholesalers from a number of countries across the European Union.

This follows detection of more active substance than expected being released from the capsules.

The batches concerned have not been distributed in Denmark.

Read more via this link:

European Medicines Agency agrees to precautionary recall of Advagraf 0.5 mg capsule batches

Cardiovascular medicine doesn't increase the risk of cancer

The European Medicines Agency, EMA, has also looked into the possible link between the use of blood pressure lowering medicines of the type angiotensin II receptor antagonists and the occurrence of new incidences of cancer. The review was requested by the Italian Medicines Agency after research had shown a possible link.

EMA has now reviewed all available data in the area. It found that it is still safe to use this type of medicine – and that the evidence does not suggest any link with cancer.

The most frequently used medicine in this group is called losartan. In Denmark it is sold under different names, one of which is Cozaar®.

Read more via this link:

European Medicines Agency concludes that benefit-risk balance of angiotensin II receptor antagonists remains positive